Progress in the treatment of atrophic age-related macular degeneration
10.3760/cma.j.issn.1005-1015.2019.01.023
- VernacularTitle:萎缩型老年性黄斑变性的治疗研究进展
- Author:
Rong XUE
1
;
Guangming WAN
Author Information
1. 郑州大学第一附属医院眼一科 450001
- Keywords:
Macular degeneration/therapy;
Geographic atrophy;
Review
- From:
Chinese Journal of Ocular Fundus Diseases
2019;35(1):94-98
- CountryChina
- Language:Chinese
-
Abstract:
Atrophic age-related macular degeneration (AMD) does not show obvious loss of visual function in the early stage,so it is not easy to be taken seriously.In the advanced stage,most of the patients suffered from macular area retinal map atrophy,which affected night vision and central vision.Drugs currently used in clinical or clinical trials to treat atrophic AMD include drugs for improving choroidal perfusion,reducing the accumulation of harmful substances,preventing oxidative stress injury,inhibiting inflammatory reactions,as well as neuroprotectants and lipid metabolism drugs.Stem cell transplantation for atrophic AMD is currently the most promising treatment.In theory,it is feasible to replace atrophic AMD with retinal photoreceptor cells and RPE cells derived from human stem cell differentiation.However,there are still many problems to be solved,such as how to improve the efficiency of directional differentiation of seed cells and how to ensure the safe and effective RPE cell transplantation and survival after transplantation.At present,several studies have found that multiple locus mutations are associated with atrophic AMD,so gene therapy also plays an important role in the development of the disease.
